Browse by Section 100 Item List
Highly Specialised Drugs Program (Community Access)
From 1 July 2015, the HSD community access arrangements better align existing HSD programme arrangements with current clinical practice and models of care, through improvements to the way clozapine for the treatment of schizophrenia (maintenance therapy only), HIV antiretroviral medicines and hepatitis B medicines are prescribed, dispensed and accessed under the s100 HSDs Programme. These changes are known as ‘HSD Community Access’.
These arrangements remove the requirement for patients and prescribers to be affiliated with a hospital setting. Patients also have greater choice about where they access their medicines, through either a community pharmacy, or a private or public hospital pharmacy. Community pharmacists are able to dispense these medicines regardless of where the medicine is prescribed.
Prescriptions for these medicines and any repeats from those prescriptions, written prior to 1 July 2015 will need to be dispensed by a hospital pharmacy in accordance with the previous arrangements.
The remuneration rates for Highly Specialised Drugs dispensed through community pharmacies are aligned to those paid to private hospitals.
Patient eligibility criteria are unchanged. Patients will continue to pay a patient co-payment which will contribute to the PBS Safety Net Record.
Further information on these arrangements is available in the respective Frequently Asked Questions (FAQs).
- MPMedical Practitioner
- NPNurse Practitioner
|Prescriber code||Item code||Name, manner of administration and form & strength||Max qty
|MPNP||10320E||LAMIVUDINElamivudine 10 mg/mL oral liquid, 240 mL||8||8||5|
|MPNP||10315X||LAMIVUDINElamivudine 100 mg tablet, 28||2||56||5|
|MPNP||10348P||LAMIVUDINElamivudine 150 mg tablet, 60||2||120||5|
|MPNP||10311Q||LAMIVUDINElamivudine 300 mg tablet, 30||2||60||5|
|MPNP||10284G||LAMIVUDINE + ZIDOVUDINElamivudine 150 mg + zidovudine 300 mg tablet, 60||2||120||5|
|MP||11289E||LANREOTIDElanreotide 120 mg/0.5 mL injection, 0.5 mL syringe||2||2||5|
|MP||11736Q||LANREOTIDElanreotide 120 mg/0.5 mL injection, 0.5 mL syringe||2||2||5|
|MP||11315M||LANREOTIDElanreotide 60 mg/0.5 mL injection, 0.5 mL syringe||2||2||5|
|MP||11316N||LANREOTIDElanreotide 90 mg/0.5 mL injection, 0.5 mL syringe||2||2||5|
|MPNP||10285H||LOPINAVIR + RITONAVIRlopinavir 100 mg + ritonavir 25 mg tablet, 60||2||120||5|
|MPNP||10327M||LOPINAVIR + RITONAVIRlopinavir 400 mg/5 mL + ritonavir 100 mg/5 mL oral liquid, 60 mL||10||10||5|
|MPNP||10272P||LOPINAVIR + RITONAVIRlopinavir 200 mg + ritonavir 50 mg tablet, 120||2||240||5|